Biophytis (BPTS) unveils Phase 3 sarcopenia trial strategy with BIO101

Rhea-AI Filing Summary

Biophytis S.A. filed a report noting that it has issued a press release unveiling its Phase 3 sarcopenia trial strategy for its investigational product BIO101 in Europe and Asia. The filing mainly serves to furnish this press release to investors as an exhibit.

UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: September 11, 2025

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On September 11, 2025, Biophytis S.A. issued a press release unveiling Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release dated September 11, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.
Date: September 11, 2025	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer

FAQ

What did Biophytis S.A. (BPTS) announce in this 6-K filing?

Biophytis S.A. reported that it issued a press release unveiling its Phase 3 sarcopenia trial strategy with BIO101 in Europe and Asia. The 6-K primarily serves to make this press release available as an official exhibit.

What is the focus of Biophytis S.A.’s new Phase 3 strategy mentioned for BPTS?

The filing states that Biophytis unveiled a Phase 3 sarcopenia trial strategy involving BIO101 in Europe and Asia. Detailed trial design, timing, or endpoints are not described in the provided excerpt, which only references the accompanying press release.

Which document is attached to Biophytis S.A. (BPTS) Form 6-K?

The Form 6-K includes Exhibit 99.1, described as a press release dated September 11, 2025. That press release contains the detailed information about the Phase 3 sarcopenia trial strategy with BIO101 in Europe and Asia.

What SEC form does Biophytis S.A. (BPTS) use for annual reporting?

The company indicates that it files annual reports under cover of Form 20-F. This confirms Biophytis S.A. is a foreign private issuer using the standard U.S. annual reporting framework for non-U.S. companies listed on U.S. markets.

Who signed the Biophytis S.A. (BPTS) September 11, 2025 Form 6-K?

The 6-K was signed on behalf of Biophytis S.A. by Stanislas Veillet, identified as Chairman and Chief Executive Officer. His signature indicates he is the authorized representative approving submission of this report to the U.S. Securities and Exchange Commission.